Chinese COVID vaccine developer Clover raised US$240 million net proceeds in Hong Kong IPO

Chinese COVID-19 vaccine developer Clover Biopharmaceuticals said on Thursday it raised US$240 million in net proceeds in initial public offering (IPO) of shares in Hong Kong.Based on the offer price …
( read original story …)